Sa1055 Final Results of a Clinical Trial of a 2-Week Lead-in Therapy With Interferon Beta Plus Ribavirin Before Peginterferon alpha-2B Plus Ribavirin for Chronic Hepatitis C With Genotype 1 and High Viral Loads

MLA

Masatomo Mori, et al. “Sa1055 Final Results of a Clinical Trial of a 2-Week Lead-in Therapy With Interferon Beta Plus Ribavirin Before Peginterferon Alpha-2B Plus Ribavirin for Chronic Hepatitis C With Genotype 1 and High Viral Loads.” Gastroenterology, vol. 144, May 2013, p. S-984. EBSCOhost, https://doi.org/10.1016/s0016-5085(13)63653-7.

APA

Masatomo Mori, Norio Horiguchi, Yuichi Yamazaki, Hiroaki Hashizume, Tatsuya Ohyama, Satoru Kakizaki, & Ken Sato. (2013). Sa1055 Final Results of a Clinical Trial of a 2-Week Lead-in Therapy With Interferon Beta Plus Ribavirin Before Peginterferon alpha-2B Plus Ribavirin for Chronic Hepatitis C With Genotype 1 and High Viral Loads. Gastroenterology, 144, S-984. https://doi.org/10.1016/s0016-5085(13)63653-7

Chicago

Masatomo Mori, Norio Horiguchi, Yuichi Yamazaki, Hiroaki Hashizume, Tatsuya Ohyama, Satoru Kakizaki, and Ken Sato. 2013. “Sa1055 Final Results of a Clinical Trial of a 2-Week Lead-in Therapy With Interferon Beta Plus Ribavirin Before Peginterferon Alpha-2B Plus Ribavirin for Chronic Hepatitis C With Genotype 1 and High Viral Loads.” Gastroenterology 144 (May): S-984. doi:10.1016/s0016-5085(13)63653-7.